SEC Company Response from Bioquest Corp (BQST) (CIK 0001568628) (BQST) — Apr 16, 2020
Bioquest Corp (BQST) (CIK 0001568628)
Date: April 16, 2020 · CIK: 0001568628 · Accession: 0001493152-20-006584
AI Filing Summary & Sentiment
File numbers found in text: 024-11151
Referenced dates: April 16, 2020
Letter
Division of Corporation Finance Office of Technology United States Securities and Exchange Commission Filed: February 11, 2020 Response Dated: March 18, 2020 File No. 024-11151 April 16, 2020
Dear Mr. Derby,
This letter sets forth the response of BioQuest Corp., (“BQST” or the “Company”) to the Staff’s comment letter dated April 16, 2020.
Amendment No. 2 to Form 1-A
Condensed Statements of Stockholders’ Deficit, page F-4
1. We note your response to prior comment 4. Please clarify whether or not the investor has the right to cancel his subscription and have the consideration refunded. We note that if you are obligated to refund consideration received in the event the subscription is canceled, amounts received should be accounted for as a liability until the underlying shares are issued.
Response: The Subscription Agreements have been fully executed, paid for, and the investor does not have the right to cancel his subscription and have the consideration refunded. As such we classified the issuance on our equity section table as stock payable to reflect the completion of the purchase.
If you have any questions or require any additional information with respect to the above, please do not hesitate to contact me at (714) 978-4425 or Andrew Coldicutt of the Law Office of Andrew Coldicutt at (619) 228-4970. Thank you for your attention to this matter.
BioQuest Corp.
/s/ Thomas Hemingway
Name: Thomas Hemingway
Title: Chief Executive Officer, Director
Show Raw Text
CORRESP
1
filename1.htm
BioQuest
Corp.
3700
Campus Drive, Suite 206
Newport
Beach, CA 92660
Phone:
(714) 978-4425
Matthew
Derby
Division
of Corporation Finance
Office
of Technology
United
States Securities and Exchange Commission
100
F Street, N.E.
Washington,
D.C. 20549
Re:
BioQuest
Corp.
Offering
Statement on Form 1-A
Filed:
February 11, 2020
Response
Dated: March 18, 2020
File
No. 024-11151
April
16, 2020
Dear
Mr. Derby,
This
letter sets forth the response of BioQuest Corp., (“BQST” or the “Company”) to the Staff’s comment
letter dated April 16, 2020.
Amendment
No. 2 to Form 1-A
Condensed
Statements of Stockholders’ Deficit, page F-4
1.
We note your response to prior comment 4. Please clarify whether or not the investor has the right to cancel his subscription
and have the consideration refunded. We note that if you are obligated to refund consideration received in the event the subscription
is canceled, amounts received should be accounted for as a liability until the underlying shares are issued.
Response:
The Subscription Agreements have been fully executed, paid for, and the investor does not have the right to cancel his subscription
and have the consideration refunded. As such we classified the issuance on our equity section table as stock payable to reflect
the completion of the purchase.
If
you have any questions or require any additional information with respect to the above, please do not hesitate to contact me at
(714) 978-4425 or Andrew Coldicutt of the Law Office of Andrew Coldicutt at (619) 228-4970. Thank you for your attention to this
matter.
BioQuest
Corp.
/s/ Thomas Hemingway
Name:
Thomas
Hemingway
Title:
Chief
Executive Officer, Director